Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA talks about the use of elotuzumab for the treatment of multiple myeloma, in the relapsed/refractory setting or in combination with other drugs, such as pomalidomide. Elotuzumab is an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), a specific receptor in the natural-killer cell population.